VSL#3® ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00367705 (ClinicalTrials.gov)	August 2009	22/8/2006	VSL#3 Treatment in Children With Crohn's Disease	Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease	Crohn's Disease	Dietary Supplement: VSL#3®;Dietary Supplement: Placebo	Hadassah Medical Organization	NULL	Not yet recruiting	6 Years	18 Years	Both	300	Phase 4	Israel

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03415711 (ClinicalTrials.gov)	April 28, 2017	5/1/2018	PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis	A Double-blind, Randomized, Placebo-controlled, Single-center, Dose-finding, Pilot Study Evaluating the Efficacy of VSL#3® in the Maintenance of Clinical and Endoscopic Remission of Mild-to-moderate UC	Ulcerative Colitis	Dietary Supplement: VSL#3®;Drug: Mesalamine;Drug: Placebo	VSL Pharmaceuticals	Actial Farmaceutica S.r.l.	Terminated	18 Years	85 Years	All	14	N/A	Italy